[
  {
    "ts": null,
    "headline": "Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)",
    "summary": "SchrÃ¶dingerâs stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. Find out why we've rated SDGR as a Buy.",
    "url": "https://finnhub.io/api/news?id=8f2c3b821c2c0c530e86a2c3bf3218939df6863ed862047d17ee38fb39aec3ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744453607,
      "headline": "Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)",
      "id": 133894812,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1150477700/image_1150477700.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "SchrÃ¶dingerâs stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. Find out why we've rated SDGR as a Buy.",
      "url": "https://finnhub.io/api/news?id=8f2c3b821c2c0c530e86a2c3bf3218939df6863ed862047d17ee38fb39aec3ae"
    }
  }
]